Assembly Biosciences, Inc. Operating Lease Cost
Assembly Biosciences, Inc. (ASMB) reported Operating Lease Cost of $851.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseCost · last filed 2026-03-19
- Assembly Biosciences, Inc. operating lease, cost for the quarter ending 2021-12-31 was $900.00K, a 48.60% decline year-over-year.
- Assembly Biosciences, Inc. operating lease, cost for the quarter ending 2021-09-30 was $902.00K, a 22.51% decline year-over-year.
- Assembly Biosciences, Inc. operating lease, cost for the quarter ending 2021-06-30 was $903.00K, a 22.02% decline year-over-year.
- Assembly Biosciences, Inc. operating lease, cost for the quarter ending 2021-03-31 was $1.14M, a 1.39% decline year-over-year.
- Assembly Biosciences, Inc. operating lease, cost for fiscal 2025 was $851.00K, a 39.94% decline from fiscal 2024.
- Assembly Biosciences, Inc. operating lease, cost for fiscal 2024 was $1.42M, a 59.60% decline from fiscal 2023.
- Assembly Biosciences, Inc. operating lease, cost for fiscal 2023 was $3.51M, a 0.06% increase from fiscal 2022.
- Assembly Biosciences, Inc. operating lease, cost for fiscal 2022 was $3.50M, a 8.72% decline from fiscal 2021.
| Period end | Operating Lease, Cost 3 month | Operating Lease, Cost 6 month | Operating Lease, Cost 9 month | Operating Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $851.00K 10-K · filed 2026-03-19 | |||
| 2024-12-31 | $1.42M 10-K · filed 2026-03-19 | |||
| 2023-12-31 | $3.51M 10-K · filed 2025-03-20 | |||
| 2022-12-31 | $3.50M 10-K · filed 2024-03-28 | |||
| 2021-12-31 | $900.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $1.80M derived: sum of 2 quarters · filed 2023-03-22 | $2.71M derived: sum of 3 quarters · filed 2023-03-22 | $3.84M 10-K · filed 2023-03-22 |
| 2021-09-30 | $902.00K 10-Q · filed 2021-11-04 | $1.80M derived: sum of 2 quarters · filed 2021-11-04 | $2.94M 10-Q · filed 2021-11-04 | $4.69M derived: sum of 4 quarters · filed 2022-03-11 |
| 2021-06-30 | $903.00K 10-Q · filed 2021-08-05 | $2.04M 10-Q · filed 2021-08-05 | $3.79M derived: sum of 3 quarters · filed 2022-03-11 | $4.95M derived: sum of 4 quarters · filed 2022-03-11 |
| 2021-03-31 | $1.14M 10-Q · filed 2021-05-06 | $2.89M derived: sum of 2 quarters · filed 2022-03-11 | $4.05M derived: sum of 3 quarters · filed 2022-03-11 | $5.21M derived: sum of 4 quarters · filed 2022-03-11 |
| 2020-12-31 | $1.75M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $2.92M derived: sum of 2 quarters · filed 2022-03-11 | $4.07M derived: sum of 3 quarters · filed 2022-03-11 | $5.21M 10-K · filed 2022-03-11 |
| 2020-09-30 | $1.16M 10-Q · filed 2021-11-04 | $2.32M derived: sum of 2 quarters · filed 2021-11-04 | $3.46M 10-Q · filed 2021-11-04 | $4.58M derived: sum of 4 quarters · filed 2021-11-04 |
| 2020-06-30 | $1.16M 10-Q · filed 2021-08-05 | $2.31M 10-Q · filed 2021-08-05 | $3.42M derived: sum of 3 quarters · filed 2021-08-05 | $4.55M derived: sum of 4 quarters · filed 2021-08-05 |
| 2020-03-31 | $1.15M 10-Q · filed 2021-05-06 | $2.26M derived: sum of 2 quarters · filed 2021-05-06 | $3.40M derived: sum of 3 quarters · filed 2021-05-06 | $4.51M derived: sum of 4 quarters · filed 2021-05-06 |
| 2019-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $2.25M derived: sum of 2 quarters · filed 2021-02-25 | $3.36M derived: sum of 3 quarters · filed 2021-02-25 | $4.45M 10-K · filed 2021-02-25 |
| 2019-09-30 | $1.14M 10-Q · filed 2020-11-05 | $2.25M derived: sum of 2 quarters · filed 2020-11-05 | $3.34M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $1.12M 10-Q · filed 2020-08-05 | $2.21M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | $1.09M 10-Q · filed 2020-05-08 | |||
| 2018-09-30 | $800.00K 10-Q · filed 2019-11-07 | $1.50M derived: sum of 2 quarters · filed 2019-11-07 | $2.30M 10-Q · filed 2019-11-07 | |
| 2018-06-30 | $700.00K 10-Q · filed 2019-08-05 | $1.50M 10-Q · filed 2019-08-05 | ||
| 2018-03-31 | $400.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |